1. Home
  2. PLSE vs PHAT Comparison

PLSE vs PHAT Comparison

Compare PLSE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$14.39

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$14.14

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
PHAT
Founded
2014
2018
Country
United States
United States
Employees
N/A
427
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
PLSE
PHAT
Price
$14.39
$14.14
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$22.00
$17.33
AVG Volume (30 Days)
167.2K
1.3M
Earning Date
11-05-2025
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$86,000.00
$147,190,000.00
Revenue This Year
N/A
$220.82
Revenue Next Year
$1,002.94
$82.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
460.30
52 Week Low
$12.56
$2.21
52 Week High
$25.00
$18.31

Technical Indicators

Market Signals
Indicator
PLSE
PHAT
Relative Strength Index (RSI) 49.53 44.02
Support Level $13.82 $13.14
Resistance Level $15.34 $14.68
Average True Range (ATR) 0.78 1.05
MACD 0.02 -0.20
Stochastic Oscillator 28.88 20.30

Price Performance

Historical Comparison
PLSE
PHAT

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: